Table 2.
Characteristics of 29 935 treatment-naive study patients at baseline and 6 months after the initiation of potent combination ART
| Characteristic | No. of patients (%) | No. of deaths (%) | Crude mortality rate per 100 person-years of follow-upa |
|---|---|---|---|
| Total | 29 935 (100) | 1134 (100) | 0.95 |
| Age at baseline (years) | |||
| 16–29 | 5081 (17) | 79 (7) | 0.4 |
| 30–39 | 13 376 (45) | 457 (40) | 0.83 |
| 40–49 | 7646 (26) | 343 (30) | 1.17 |
| ≥50 | 3832 (13) | 255 (22) | 1.75 |
| Sex | |||
| Males | 21 773 (73) | 931 (82) | 1.05 |
| Females | 8162 (27) | 203 (18) | 0.68 |
| Risk group | |||
| MSM | 11 960 (40 | 388 (34) | 0.76 |
| Heterosexuals | 13 575 (45) | 392 (35) | 0.79 |
| IDUs | 4400 (15) | 354 (31) | 1.95 |
| Clinical CDC stage at baseline | |||
| A/B | 23 197 (77) | 668 (59) | 0.72 |
| C | 6738 (23) | 466 (41) | 1.77 |
| CD4 count (cells/µl) Baseline measurement | |||
| <25 | 3007 (10) | 219 (19) | 1.84 |
| 25–49 | 1913 (6) | 123 (11) | 1.64 |
| 50–99 | 3088 (10) | 170 (15) | 1.4 |
| 100–199 | 5849 (20) | 229 (20) | 1.06 |
| 200–349 | 8635 (29) | 226 (20) | 0.71 |
| ≥350 | 7443 (25) | 167 (15) | 0.49 |
| 6-month measurement | |||
| <25 | 442 (1) | 101 (9) | 7.41 |
| 25–49 | 599 (2) | 88 (8) | 3.95 |
| 50–99 | 1923 (6) | 147 (13) | 1.9 |
| 100–199 | 5189 (17) | 255 (22) | 1.27 |
| 200–349 | 8092 (27) | 261 (23) | 0.86 |
| ≥350 | 13 690 (46) | 282 (25) | 0.49 |
| Plasma HIV-1 RNA level (copies/ml) Baseline measurement | |||
| ≤500 (undetectable) | 433 (1) | 15 (1) | 0.94 |
| 501–9999 | 3373 (11) | 89 (8) | 0.67 |
| 10 000–99 999 | 11 931 (40) | 350 (31) | 0.73 |
| ≥100 000 | 14 198 (47) | 680 (60) | 1.22 |
| 6-month measurement | |||
| ≤500 (undetectable) | 23 539 (79) | 674 (59) | 0.73 |
| 501–9999 | 3287 (11) | 165 (15) | 1.14 |
| 10 000–99 999 | 1984 (7) | 142 (13) | 1.83 |
| ≥100 000 | 1125 (4) | 153 (13) | 3.71 |
aCalculation of time at risk started at 6 months.